Challenges in cancer research and multifaceted approaches for cancer biomarker quest

FEBS Letters

Volumn 583, Issue 11, 2009, Pages 1772-1784

  Martinkova, Jirina ^a   Gadher, Suresh Jivan ^b   Hajduch, Marian ^c   Kovarova, Hana ^a  

^a INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^b Millipore Bioscience   (United States)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Anti cancer therapy; Cancer biomarker; Cancer research; Genomics; Proteomics; Transcriptomics

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; FLUOROURACIL; GEMCITABINE; IDARUBICIN; IFOSFAMIDE; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NITROSOUREA DERIVATIVE; RAPAMYCIN; TEMOZOLOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

CANCER CLASSIFICATION; CANCER RESEARCH; CHROMOSOME REARRANGEMENT; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE TRANSLOCATION; GENOMICS; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHORT SURVEY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSCRIPTOMICS; TREATMENT RESPONSE;

HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349192585     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.03.042     Document Type: Short Survey

References (133)

1. Skvortsov S., Skvortsova I., Stasyk T., Schiefermeier N., Neher A., Gunkel A.R., Bonn G.K., Huber L.A., Lukas P., Pleiman C.M., and Zwierzina H. Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines. Mol. Cancer Ther. 6 (2007) 1898-1908
2. Skvortsova I., Skvortsov S., Stasyk T., Raju U., Popper B.A., Schiestl B., von Guggenberg E., Neher A., Bonn G.K., Huber L.A., and Lukas P. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8 (2008) 4521-4533
3. Huang, W., Yu, L.F., Zhong, J., Wu, W., Zhu, J.Y., Jiang, F.X., and Wu, Y.L. (2008) Stat3 is involved in angiotensin ii-induced expression of MMP2 in gastric cancer cells. Dig. Dis. Sci. (December 11, Epub ahead of print).
4. Chong P.K., Lee H., Kong J.W., Loh M.C., Wong C.H., and Lim Y.P. Phosphoproteomics, oncogenic signaling and cancer research. Proteomics 8 (2008) 4370-4382
5. Sathornsumetee S., Reardon D.A., Desjardins A., Quinn J.A., Vredenburgh J.J., and Rich J.N. Molecularly targeted therapy for malignant glioma. Cancer 110 (2007) 13-24
6. Prasad N.K. SHIP2 phosphoinositol phosphatase positively regulates EGFR-Akt pathway, CXCR4 expression, and cell migration in MDA-MB-231 breast cancer cells. Int. J. Oncol. 34 (2009) 97-105
7. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
8. Smith L.T., Otterson G.A., and Plass C. Unraveling the epigenetic code of cancer for therapy. Trends Genet. 23 (2007) 449-456
9. Hake S.B., Xiao A., and Allis C.D. Linking the epigenetic 'language' of covalent histone modifications to cancer. Br. J. Cancer. 90 (2004) 761-769
10. Pan L.N., Lu J., and Huang B. HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol. Immunol. 4 (2007) 337-343
11. Weissman I.L., Anderson D.J., and Gage F. Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu. Rev. Cell Dev. Biol. 17 (2001) 387-403
12. Molofsky A.V., Pardal R., and Morrison S.J. Diverse mechanisms regulate stem cell self-renewal. Curr. Opin. Cell Biol. 16 (2004) 700-707
13. Dalerba P., Cho R.W., and Clarke M.F. Cancer stem cells: models and concepts. Annu. Rev. Med. 58 (2007) 267-284
14. Zhu L., Gibson P., Currle D.S., Tong Y., Richardson R.J., Bayazitov I.T., Poppleton H., Zakharenko S., Ellison D.W., and Gilbertson R.J. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457 7229 (2009) 603-607
15. Trumpp A., and Wiestler O.D. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 5 (2008) 337-347
16. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., Hjelmeland A.B., and Rich J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68 (2008) 6043-6048
17. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G., and Reddy V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 106 (2009) 268-273
18. Wallin J.E., Friberg L.E., and Karlsson M.O. A tool for neutrophil guided dose adaptation in chemotherapy. Comput. Meth. Programs Biomed. 93 3 (2009) 283-291
19. Longo R., and Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev. Mol. Diagn. 8 (2008) 301-314
20. Tortora G., Ciardiello F., and Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat. Clin. Pract. Oncol. 5 (2008) 521-530
21. Sarmiento R., Bonginelli P., Cacciamani F., Salerno F., and Gasparini G. Gastrointestinal stromal tumors (GISTs): from science to targeted therapy. Int. J. Biol. Markers 23 (2008) 96-110
22. Eyler C.E., Foo W.C., LaFiura K.M., McLendon R.E., Hjelmeland A.B., and Rich J.N. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells 26 (2008) 3027-3036
23. Gasparini G., Longo R., Torino F., Gattuso D., Morabito A., and Toffoli G. Is tailored therapy feasible in oncology?. Crit. Rev. Oncol. Hematol. 57 (2006) 79-101
24. Sathornsumetee S., and Rich J.N. Designer therapies for glioblastoma multiforme. Ann. NY Acad. Sci. 1142 (2008) 108-132
25. Sathornsumetee S., Rich J.N., and Reardon D.A. Diagnosis and treatment of high-grade astrocytoma. Neurol. Clin. 25 (2007) 1111-1139 x
26. Longo R., Torino F., and Gasparini G. Targeted therapy of breast cancer. Curr. Pharm. Des. 13 (2007) 497-517
27. Gasparini G., Gion M., Mariani L., Papaldo P., Crivellari D., Filippelli G., Morabito A., Silingardi V., Torino F., Spada A., Zancan M., De Sio L., Caputo A., Cognetti F., Lambiase A., and Amadori D. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res. Treat. 101 (2007) 355-365
28. O'Reilly M.S. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin. Cancer Res. 8 (2002) 3309-3310
29. Hanash S. Integrated global profiling of cancer. Nat. Rev. Cancer 4 (2004) 638-644
30. Pollack J.R., Sorlie T., Perou C.M., Rees C.A., Jeffrey S.S., Lonning P.E., Tibshirani R., Botstein D., Borresen-Dale A.L., and Brown P.O. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. USA 99 (2002) 12963-12968
31. Wu R., Lin L., Beer D.G., Ellenson L.H., Lamb B.J., Rouillard J.M., Kuick R., Hanash S., Schwartz D.R., Fearon E.R., and Cho K.R. Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas. Am. J. Pathol. 162 (2003) 1603-1610
32. Grosso A.R., Martins S., and Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep. 9 (2008) 1087-1093
33. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., and Botstein D. Molecular portraits of human breast tumours. Nature 406 (2000) 747-752
34. Collins F.S., Green E.D., Guttmacher A.E., and Guyer M.S. A vision for the future of genomics research. Nature 422 (2003) 835-847
35. Ntzani E.E., and Ioannidis J.P. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 362 (2003) 1439-1444
36. Simon R. Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarray data. Br. J. Cancer 89 (2003) 1599-1604
37. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., and Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98 (2001) 10869-10874
38. Maxwell P.J., Longley D.B., Latif T., Boyer J., Allen W., Lynch M., McDermott U., Harkin D.P., Allegra C.J., and Johnston P.G. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res. 63 (2003) 4602-4606
39. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., Maeda E., Noguchi S., and Kato K. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 23 (2005) 422-431
40. Jansen M.P., Foekens J.A., van Staveren I.L., Dirkzwager-Kiel M.M., Ritstier K., Look M.P., Meijer-van Gelder M.E., Sieuwerts A.M., Portengen H., Dorssers L.C., Klijn J.G., and Berns E.M. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J. Clin. Oncol. 23 (2005) 732-740
41. Ayers M., Symmans W.F., Stec J., Damokosh A.I., Clark E., Hess K., Lecocke M., Metivier J., Booser D., Ibrahim N., Valero V., Royce M., Arun B., Whitman G., Ross J., Sneige N., Hortobagyi G.N., and Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22 (2004) 2284-2293
42. Kunz M. Genomic signatures for individualized treatment of malignant tumors. Curr. Drug. Discov. Technol. 5 (2008) 9-14
43. Horning J.L., Sahoo S.K., Vijayaraghavalu S., Dimitrijevic S., Vasir J.K., Jain T.K., Panda A.K., and Labhasetwar V. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol. Pharm. 5 (2008) 849-862
44. Abramovitz M., Ordanic-Kodani M., Wang Y., Li Z., Catzavelos C., Bouzyk M., Sledge Jr. G.W., Moreno C.S., and Leyland-Jones B. Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques 44 (2008) 417-423
45. Bibikova M., Yeakley J.M., Wang-Rodriguez J., and Fan J.B. Quantitative expression profiling of RNA from formalin-fixed, paraffin-embedded tissues using randomly assembled bead arrays. Meth. Mol. Biol. 439 (2008) 159-177
46. Ravo M., Mutarelli M., Ferraro L., Grober O.M., Paris O., Tarallo R., Vigilante A., Cimino D., De Bortoli M., Nola E., Cicatiello L., and Weisz A. Quantitative expression profiling of highly degraded RNA from formalin-fixed, paraffin-embedded breast tumor biopsies by oligonucleotide microarrays. Lab. Invest. 88 (2008) 430-440
47. Esquela-Kerscher A., and Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6 (2006) 259-269
48. Negrini M., Ferracin M., Sabbioni S., and Croce C.M. MicroRNAs in human cancer: from research to therapy. J. Cell Sci. 120 (2007) 1833-1840
49. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., and Golub T.R. MicroRNA expression profiles classify human cancers. Nature 435 (2005) 834-838
50. Kelloff G.J., and Sigman C.C. New science-based endpoints to accelerate oncology drug development. Eur. J. Cancer. 41 (2005) 491-501
51. Hajduch M., Skalnikova H., Halada P., Vydra D., Dzubak P., Dziechciarkova M., Strnad M., Radioch D., and Kovarova H. Cyclin-dependent kinase inhibitors and cancer: usefulness of proteomic approaches in assessment of the molecular mechanisms and efficacy of novel therapeutics. In: Eyk J.E., and Dunn M.J. (Eds). Clinical Proteomics (2007), Wiley-VCH 177-202
52. Meyer H.E., and Stuhler K. High-performance proteomics as a tool in biomarker discovery. Proteomics 7 Suppl. 1 (2007) 18-26
53. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pillai S., Dey S., Daniels S., Purkayastha S., Juhasz P., Martin S., Bartlet-Jones M., He F., Jacobson A., and Pappin D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell Proteomics 3 (2004) 1154-1169
54. Skalnikova H., Rehulka P., Chmelik J., Martinkova J., Zilvarova M., Gadher S.J., and Kovarova H. Relative quantitation of proteins fractionated by the ProteomeLab PF 2D system using isobaric tags for relative and absolute quantitation (iTRAQ). Anal. Bioanal. Chem. 389 (2007) 1639-1645
55. Bantscheff M., Schirle M., Sweetman G., Rick J., and Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 389 (2007) 1017-1031
56. Hu Z., Hood L., and Tian Q. Quantitative proteomic approaches for biomarker discovery. Proteomics Clin. Appl. 1 (2007) 1036-1041
57. Spurrier B., Honkanen P., Holway A., Kumamoto K., Terashima M., Takenoshita S., Wakabayashi G., Austin J., and Nishizuka S. Protein and lysate array technologies in cancer research. Biotechnol. Adv. 26 (2008) 361-369
58. Pollard H.B., Srivastava M., Eidelman O., Jozwik C., Rothwell S.W., Mueller G.P., Jacobowitz D.M., Darling T., Guggino W.B., Wright J., Zeitlin P.L., and Paweletz C.P. Protein microarray platforms for clinical proteomics. Proteomics Clin. Appl. 1 (2007) 934-952
59. Hober S., and Uhlen M. Human protein atlas and the use of microarray technologies. Curr. Opin. Biotechnol. 19 (2008) 30-35
60. Deininger, S.O., Ebert, M.P., Futterer, A., Gerhard, M., and Rocken, C. (2008) MALDI imaging combined with hierarchical clustering as a new tool for the interpretation of complex human cancers. J. Proteome Res. (October 23, Epub ahead of print).
61. Rezaul K., Wilson L.L., and Han D.K. Direct tissue proteomics in human diseases: potential applications to melanoma research. Expert Rev. Proteomics 5 (2008) 405-412
62. Ahn S.M., and Simpson R.J. Body fluid proteomics: prospects for biomarker discovery. Proteomics Clin. Appl. 1 (2007) 1004-1015
63. Yip T.T., and Lomas L. SELDI ProteinChip array in oncoproteomic research. Technol. Cancer Res. Treat. 1 (2002) 273-280
64. Lopez M.F., Mikulskis A., Kuzdzal S., Golenko E., Petricoin III E.F., Liotta L.A., Patton W.F., Whiteley G.R., Rosenblatt K., Gurnani P., Nandi A., Neill S., Cullen S., O'Gorman M., Sarracino D., Lynch C., Johnson A., Mckenzie W., and Fishman D. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin. Chem. 53 (2007) 1067-1074
65. Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
66. Maurya P., Meleady P., Dowling P., and Clynes M. Proteomic approaches for serum biomarker discovery in cancer. Anticancer Res. 27 (2007) 1247-1255
67. Qiu Y., Patwa T.H., Xu L., Shedden K., Misek D.E., Tuck M., Jin G., Ruffin M.T., Turgeon D.K., Synal S., Bresalier R., Marcon N., Brenner D.E., and Lubman D.M. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res. 7 (2008) 1693-1703
68. Kirmiz C., Li B., An H.J., Clowers B.H., Chew H.K., Lam K.S., Ferrige A., Alecio R., Borowsky A.D., Sulaimon S., Lebrilla C.B., and Miyamoto S. A serum glycomics approach to breast cancer biomarkers. Mol. Cell Proteomics 6 (2007) 43-55
69. Bengtsson S., Krogh M., Szigyarto C.A., Uhlen M., Schedvins K., Silfversward C., Linder S., Auer G., Alaiya A., and James P. Large-scale proteomics analysis of human ovarian cancer for biomarkers. J. Proteome Res. 6 (2007) 1440-1450
70. Kondo T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 41 (2008) 626-634
71. Suehara Y., Kondo T., Seki K., Shibata T., Fujii K., Gotoh M., Hasegawa T., Shimada Y., Sasako M., Shimoda T., Kurosawa H., Beppu Y., Kawai A., and Hirohashi S. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin. Cancer Res. 14 (2008) 1707-1717
72. Sodek K.L., Evangelou A.I., Ignatchenko A., Agochiya M., Brown T.J., Ringuette M.J., Jurisica I., and Kislinger T. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Mol. Biosyst. 4 (2008) 762-773
73. Hudson M.E., Pozdnyakova I., Haines K., Mor G., and Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. USA 104 (2007) 17494-17499
74. Ma Y., Ding Z., Qian Y., Shi X., Castranova V., Harner E.J., and Guo L. Predicting cancer drug response by proteomic profiling. Clin. Cancer Res. 12 (2006) 4583-4589
75. Nishizuka S., Charboneau L., Young L., Major S., Reinhold W.C., Waltham M., Kouros-Mehr H., Bussey K.J., Lee J.K., Espina V., Munson P.J., Petricoin III E., Liotta L.A., and Weinstein J.N. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 100 (2003) 14229-14234
76. Chabner B.A., and Roberts Jr. T.G. Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5 (2005) 65-72
77. Trog D., Fountoulakis M., Friedlein A., and Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 6 (2006) 2924-2930
78. Moller A., Malerczyk C., Volker U., Stoppler H., and Maser E. Monitoring daunorubicin-induced alterations in protein expression in pancreas carcinoma cells by two-dimensional gel electrophoresis. Proteomics 2 (2002) 697-705
79. Chen S.T., Pan T.L., Tsai Y.C., and Huang C.M. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 181 (2002) 95-107
80. Casado P., Zuazua-Villar P., del Valle E., Martinez-Campa C., Lazo P.S., and Ramos S. Vincristine regulates the phosphorylation of the antiapoptotic protein HSP27 in breast cancer cells. Cancer Lett. 247 (2007) 273-282
81. Petrak J., Ivanek R., Toman O., Cmejla R., Cmejlova J., Vyoral D., Zivny J., and Vulpe C.D. Deja vu in proteomics. A hit parade of repeatedly identified differentially expressed proteins. Proteomics 8 (2008) 1744-1749
82. Campostrini N., Marimpietri D., Totolo A., Mancone C., Fimia G.M., Ponzoni M., and Righetti P.G. Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line. Proteomics 6 (2006) 4420-4431
83. Schmidt F., Hustoft H.K., Strozynski M., Dimmler C., Rudel T., and Thiede B. Quantitative proteome analysis of cisplatin-induced apoptotic Jurkat T cells by stable isotope labeling with amino acids in cell culture, SDS-PAGE, and LC-MALDI-TOF/TOF MS. Electrophoresis 28 (2007) 4359-4368
84. Kovarova H., Halada P., Man P., Dzubak P., and Hajduch M. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol. Cancer Res. Treat. 1 (2002) 247-256
85. Kovarova H., Hajduch M., Korinkova G., Halada P., Krupickova S., Gouldsworthy A., Zhelev N., and Strnad M. Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor. Bohemine. Electrophoresis 21 (2000) 3757-3764
86. Boyd Z.S., Wu Q.J., O'Brien C., Spoerke J., Savage H., Fielder P.J., Amler L., Yan Y., and Lackner M.R. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol. Cancer Ther. 7 (2008) 3695-3706
87. Kim, H.J., Kang, H.J., Lee, H., Lee, S.T., Yu, M.H., Kim, H., and Lee, C. (2009) Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. (February 2, Epub ahead of print).
88. Tian M., Cui Y.Z., Song G.H., Zong M.J., Zhou X.Y., Chen Y., and Han J.X. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8 (2008) 241
89. Hoagland IV L.F., Campa M.J., Gottlin E.B., Herndon II J.E., and Patz Jr. E.F. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer 110 (2007) 2260-2268
90. Kawai A., Kondo T., Suehara Y., Kikuta K., and Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin. Orthop. Relat. Res. 466 (2008) 2099-2106
91. Orenes-Pinero E., Corton M., Gonzalez-Peramato P., Algaba F., Casal I., Serrano A., and Sanchez-Carbayo M. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J. Proteome Res. 6 (2007) 4440-4448
92. Di Michele M., Della Corte A., Cicchillitti L., Del Boccio P., Urbani A., Ferlini C., Scambia G., Donati M.B., and Rotilio D. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim. Biophys. Acta 1794 (2009) 225-236
93. Cicchillitti, L., Di Michele, M., Urbani, A., Ferlini, C., Donati, M.B., Scambia, G., and Rotilio, D. (2009) Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. J. Proteome Res. (February 2, Epub ahead of print).
94. Orimo T., Ojima H., Hiraoka N., Saito S., Kosuge T., Kakisaka T., Yokoo H., Nakanishi K., Kamiyama T., Todo S., Hirohashi S., and Kondo T. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 48 (2008) 1851-1863
95. Liu Y.F., Xiao Z.Q., Li M.X., Li M.Y., Zhang P.F., Li C., Li F., Chen Y.H., Yi H., Yao H.X., and Chen Z.C. Quantitative proteome analysis reveals annexin A3 as a novel biomarker in lung adenocarcinoma. J. Pathol. 217 (2009) 54-64
96. Giusti L., Iacconi P., Ciregia F., Giannaccini G., Donatini G.L., Basolo F., Miccoli P., Pinchera A., and Lucacchini A. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 7 (2008) 4079-4088
97. Bouchal P., Roumeliotis T., Hrstka R., Nenutil R., Vojtesek B., and Garbis S.D. Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J. Proteome Res. 8 (2009) 362-373
98. Garbis S.D., Tyritzis S.I., Roumeliotis T., Zerefos P., Giannopoulou E.G., Vlahou A., Kossida S., Diaz J., Vourekas S., Tamvakopoulos C., Pavlakis K., Sanoudou D., and Constantinides C.A. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J. Proteome Res. 7 (2008) 3146-3158
99. Ralhan R., Desouza L.V., Matta A., Chandra Tripathi S., Ghanny S., Datta Gupta S., Bahadur S., and Siu K.W. Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol. Cell Proteomics 7 (2008) 1162-1173
100. Chaerkady R., Harsha H.C., Nalli A., Gucek M., Vivekanandan P., Akhtar J., Cole R.N., Simmers J., Schulick R.D., Singh S., Torbenson M., Pandey A., and Thuluvath P.J. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma. J. Proteome Res. 7 (2008) 4289-4298
101. Chen R., Pan S., Yi E.C., Donohoe S., Bronner M.P., Potter J.D., Goodlett D.R., Aebersold R., and Brentnall T.A. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6 (2006) 3871-3879
102. Sun Y., Mi W., Cai J., Ying W., Liu F., Lu H., Qiao Y., Jia W., Bi X., Lu N., Liu S., Qian X., and Zhao X. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J. Proteome Res. 7 (2008) 3847-3859
103. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., Molina H., Jensen O.N., Hruban R.H., Goggins M.G., Maitra A., and Pandey A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell Proteomics 5 (2006) 157-171
104. Kristiansen T.Z., Harsha H.C., Gronborg M., Maitra A., and Pandey A. Differential membrane proteomics using 18O-labeling to identify biomarkers for cholangiocarcinoma. J. Proteome Res. 7 (2008) 4670-4677
105. Ueda K., Katagiri T., Shimada T., Irie S., Sato T.A., Nakamura Y., and Daigo Y. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J. Proteome Res. 6 (2007) 3475-3483
106. Whiteaker J.R., Zhang H., Zhao L., Wang P., Kelly-Spratt K.S., Ivey R.G., Piening B.D., Feng L.C., Kasarda E., Gurley K.E., Eng J.K., Chodosh L.A., Kemp C.J., McIntosh M.W., and Paulovich A.G. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J. Proteome Res. 6 (2007) 3962-3975
107. Pan J., Chen H.Q., Sun Y.H., Zhang J.H., and Luo X.Y. Comparative proteomic analysis of non-small-cell lung cancer and normal controls using serum label-free quantitative shotgun technology. Lung 186 (2008) 255-261
108. Huang S.K., Darfler M.M., Nicholl M.B., You J., Bemis K.G., Tegeler T.J., Wang M., Wery J.P., Chong K.K., Nguyen L., Scolyer R.A., and Hoon D.S. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. PLoS ONE. 4 (2009) e4430
109. Cheng L., Zhou L., Tao L., Zhang M., Cui J., and Li Y. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis. J. Cancer Res. Clin. Oncol. 134 (2008) 769-776
110. Han K.Q., Huang G., Gao C.F., Wang X.L., Ma B., Sun L.Q., and Wei Z.J. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am. J. Clin. Oncol. 31 (2008) 133-139
111. Lim J.Y., Cho J.Y., Paik Y.H., Chang Y.S., and Kim H.G. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int. J. Biol. Markers 22 (2007) 281-286
112. Cui J., Kang X., Dai Z., Huang C., Zhou H., Guo K., Li Y., Zhang Y., Sun R., Chen J., Li Y., Tang Z., Uemura T., and Liu Y. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J. Cancer Res. Clin. Oncol. 133 (2007) 825-834
113. Engwegen J.Y., Mehra N., Haanen J.B., Bonfrer J.M., Schellens J.H., Voest E.E., and Beijnen J.H. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab. Invest. 87 (2007) 161-172
114. Shirai Y., Sogawa K., Yamaguchi T., Sudo K., Nakagawa A., Sakai Y., Ishihara T., Sunaga M., Nezu M., Tomonaga T., Miyazaki M., Saisho H., and Nomura F. Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas. Hepatogastroenterology 55 (2008) 1824-1829
115. Holcakova J., Hernychova L., Bouchal P., Brozkova K., Zaloudik J., Valik D., Nenutil R., and Vojtesek B. Identification of alphaB-crystallin, a biomarker of renal cell carcinoma by SELDI-TOF MS. Int. J. Biol. Markers 23 (2008) 48-53
116. Leong S., Christopherson R.I., and Baxter R.C. Profiling of apoptotic changes in human breast cancer cells using SELDI-TOF mass spectrometry. Cell Physiol. Biochem. 20 (2007) 579-590
117. Chaurand P., Rahman M.A., Hunt T., Mobley J.A., Gu G., Latham J.C., Caprioli R.M., and Kasper S. Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol. Cell Proteomics 7 (2008) 411-423
118. Schwamborn K., Krieg R.C., Reska M., Jakse G., Knuechel R., and Wellmann A. Identifying prostate carcinoma by MALDI-Imaging. Int. J. Mol. Med. 20 (2007) 155-159
119. Kilic A., Schuchert M.J., Luketich J.D., Landreneau R.J., Lokshin A.E., Bigbee W.L., and El-Hefnawy T. Use of novel autoantibody and cancer-related protein arrays for the detection of esophageal adenocarcinoma in serum. J. Thorac. Cardiovasc. Surg. 136 (2008) 199-204
120. Ellmark P., Ingvarsson J., Carlsson A., Lundin B.S., Wingren C., and Borrebaeck C.A. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol. Cell Proteomics 5 (2006) 1638-1646
121. Sanchez-Carbayo M., Socci N.D., Lozano J.J., Haab B.B., and Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168 (2006) 93-103
122. Vazquez-Martin A., Colomer R., and Menendez J.A. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J. Cancer 43 (2007) 1117-1124
123. Ghosh S., Sullivan C.A., Zerkowski M.P., Molinaro A.M., Rimm D.L., Camp R.L., and Chung G.G. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum. Pathol. 39 (2008) 1835-1843
124. Chung Y.L., Lee M.Y., Horng C.F., Jian J.J., Cheng S.H., Tsai S.Y., Hsieh C.I., Yen L.K., and Lin C.Y. Use of combined molecular biomarkers for prediction of clinical outcomes in locally advanced tonsillar cancers treated with chemoradiotherapy alone. Head Neck 31 (2009) 9-20
125. Hua S., Kallen C.B., Dhar R., Baquero M.T., Mason C.E., Russell B.A., Shah P.K., Liu J., Khramtsov A., Tretiakova M.S., Krausz T.N., Olopade O.I., Rimm D.L., and White K.P. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 4 (2008) 188
126. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., Yue L., Bray-Ward P., and Ward D.C. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 7677-7682
127. Verrills N.M., Walsh B.J., Cobon G.S., Hains P.G., and Kavallaris M. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278 (2003) 45082-45093
128. Yim E.K., Lee K.H., Bae J.S., Namkoong S.E., Um S.J., and Park J.S. Proteomic analysis of antiproliferative effects by treatment of 5-fluorouracil in cervical cancer cells. DNA Cell Biol. 23 (2004) 769-776
129. Yim E.K., Lee S.B., Lee K.H., Kim C.J., and Park J.S. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. Int. J. Gynecol. Cancer 16 (2006) 1321-1329
130. Yim E.K., Lee K.H., Kim C.J., and Park J.S. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int. J. Gynecol. Cancer 16 (2006) 690-697
131. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., Zunino F., and Righetti P.G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 4 (2004) 3246-3267
132. Cecconi D., Scarpa A., Donadelli M., Palmieri M., Hamdan M., Astner H., and Righetti P.G. Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis 24 (2003) 1871-1878
133. Cecconi D., Donadelli M., Scarpa A., Milli A., Palmieri M., Hamdan M., Areces L.B., Rappsilber J., and Righetti P.G. Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. J. Proteome Res. 4 (2005) 1909-1916